Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -4.63
- Piotroski Score 1.00
- Grade Sector Perform
- Symbol (AVTX)
- Company Avalo Therapeutics, Inc.
- Price $11.75
- Changes Percentage (-5.32%)
- Change -$0.66
- Day Low $11.70
- Day High $12.41
- Year High $34.46
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/27/2025
- Fiscal Year End N/A
- Average Stock Price Target $35.00
- High Stock Price Target $35.00
- Low Stock Price Target $35.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$51.00
- Trailing P/E Ratio -0.2
- Forward P/E Ratio -0.2
- P/E Growth -0.2
- Net Income $-31,544,000
Income Statement
Quarterly
Annual
Latest News of AVTX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Avantium (AMS:AVTX) investors are sitting on a loss of 23% if they invested three years ago
Avantium N.V. (AMS:AVTX) has seen a 43% drop in share price in three years, outperforming the market decline of 7.7%. Despite a recent 13% decrease, its revenue growth of 27% annually is promising....
By Yahoo! Finance | 6 days ago
